Emergent Biosolutions (EBS) Misses Q2 EPS by 2c; Mixed Guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.49 -1.32%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q2 EPS of $0.21, $0.02 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $70.4 million versus the consensus estimate of $76.2 million.
Emergent Biosolutions sees FY2012 revenue of $60-$70 million, versus the consensus of $78.32 million.
Emergent Biosolutions sees FY2012 revenue of $280-$300 million, versus the consensus of $292.99 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Emergent Biosolutions sees FY2012 revenue of $60-$70 million, versus the consensus of $78.32 million.
Emergent Biosolutions sees FY2012 revenue of $280-$300 million, versus the consensus of $292.99 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Assembly Biosciences (ASMB) Tops Q2 EPS by 53c
- Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
